The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10588 malaria professionals are enjoying the free benefits of MalariaWorld today

Plasmodium vivax

Long-Term Humoral and Cellular Immune Responses Elicited by a Heterologous Plasmodium vivax Apical Membrane Antigen 1 Protein Prime/Adenovirus Boost Immunization Protocol

September 8, 2011 - 09:14 -- Patrick Sampao
Author(s): 
Leoneide Érica Maduro Bouillet, Mariana Oliveira Dias, Oscar Bruna-Romero, et al.
Reference: 
Infect. Immun., Sep 2011; 79: 3642 - 3652.

We show here that when it is administered as a recombinant protein (P) in Montanide ISA720 adjuvant, followed by a recombinant human type 5 adenovirus (Ad), intense and long-lasting Plasmodium vivax AMA-1-specific antibody responses (including both IgG1 and IgG2a), as well as proliferative memory T cell responses, can be detected in immunized mice.

Medical Condition: 

Open Access | Evaluation of the Safety and Immunogenicity in Rhesus Monkeys of a Recombinant Malaria Vaccine for Plasmodium vivax with a Synthetic Toll-Like Receptor 4 Agonist Formulated in an Emulsion

September 8, 2011 - 08:40 -- Patrick Sampao
Author(s): 
Joanne M. Lumsden, Sathit Pichyangkul, Anjali Yadava, et al.
Reference: 
Infection and Immunity, September 2011,p. 3492-3500, Vol. 79, No. 9

In this study rhesus monkeys were immunized intramuscularly three times with VMP001 in combination with a stable emulsion (SE) or a synthetic Toll-like receptor 4 (TLR4) agonist (glucopyranosyl lipid A [GLA]) in SE (GLA-SE).

Medical Condition: 
Medical Treatment: 

Open Access | Recent increase of genetic diversity in Plasmodium vivax population in the Republic of Korea

September 8, 2011 - 07:50 -- Kabogo Ndegwa
Author(s): 
Honma H, Kim JY, Palacpac NMQ, Mita T, Lee W, Horii T and Tanabe K
Reference: 
Malaria Journal 2011, 10:257 (7 September 2011)

The present microsatellite analysis clearly showed recent increase of genetic diversity and recent relaxation of the strong population structure observed in 1997-2000.

Country: 
Medical Condition: 

Challenges in antimalarial drug discovery

September 8, 2011 - 06:40 -- Kabogo Ndegwa
Author(s): 
Jeremy N Burrows, Didier Leroy, Julie Lotharius, David Waterson
Reference: 
Future Medicinal Chemistry, September 2011, Vol. 3, No. 11, Pages 1401-1412

Malaria is one of the most devastating diseases in the world, affecting almost 225 million people a year, and causing over 780,000 deaths, most of which are children under the age of 5 years.

Medical Treatment: 

Open Access | Development and evaluation of a prototype non-woven fabric filter for purification of malaria-infected blood

August 30, 2011 - 11:40 -- Kabogo Ndegwa
Author(s): 
Tao Z, Xia H, Cao J, Gao Q
Reference: 
Malaria Journal 2011, 10:251 (25 August 2011

NWF filter filtration removed most leukocytes from malaria-infected blood, and the recovery rate of RBCs was higher than with CF11 column method.

Open Access | Environmental, entomological, socioeconomic and behavioural risk factors for malaria attacks in Amerindian children of Camopi, French Guiana

August 24, 2011 - 15:31 -- Kabogo Ndegwa
Author(s): 
Stefani A, Hanf M, Nacher M, Girod R, Carme B
Reference: 
Malaria Journal 2011, 10:246 (23 August 2011)

Malaria incidence in children remains high in young children despite the appearance of immunity in children around three years of age.

Person: 
Medical Condition: 

Characterization of Treatment Failure in Efficacy Trials of Drugs against Plasmodium vivax by Genotyping Neutral and Drug Resistance-Associated Markers

August 19, 2011 - 08:20 -- Patrick Sampao
Author(s): 
Celine Barnadas, Cristian Koepfli, Harin A. Karunajeewa, Peter M. Siba, Timothy M. E. Davis, and Ivo Mueller
Reference: 
Antimicrobial Agents and Chemotherapy, September 2011,p. 4479-4481, Vol. 55, No. 9

Plasmodium vivax intervention trials customarily report uncorrected treatment failure rates.

Technology: 
Medical Condition: 

Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria

August 18, 2011 - 11:30 -- Kabogo Ndegwa
Author(s): 
David Sinclair, Nithya Gogtay, Felicity Brand, Piero Olliaro
Reference: 
Cochrane Infectious Diseases Group, 6 JUL 2011

Two authors independently assessed trials for eligibility and risk of bias, and extracted data.

Medical Condition: 
Medical Treatment: 

Long-Term Humoral and Cellular Immune Responses Elicited by a Heterologous Plasmodium vivax Apical Membrane Antigen 1 Protein Prime/Adenovirus Boost Immunization Protocol

August 17, 2011 - 09:51 -- Patrick Sampao
Author(s): 
Leoneide Érica Maduro Bouillet, Mariana Oliveira Dias, Oscar Bruna-Romero, et al.
Reference: 
Infect. Immun., Sep 2011; 79: 3642 - 3652.

These results give further support to the need for preclinical studies of P. vivax vaccine candidate AMA-1 administered in prime/boost protocols that include recombinant proteins and adenoviral vectors.

Medical Condition: 
Medical Treatment: 

Open Access | Evaluation of the Safety and Immunogenicity in Rhesus Monkeys of a Recombinant Malaria Vaccine for Plasmodium vivax with a Synthetic Toll-Like Receptor 4 Agonist Formulated in an Emulsion

August 17, 2011 - 09:37 -- Patrick Sampao
Author(s): 
Joanne M. Lumsden, Sathit Pichyangkul, Anjali Yadava, et al.
Reference: 
Infect. Immun., Sep 2011; 79: 3492 - 3500.

In this study rhesus monkeys were immunized intramuscularly three times with VMP001 in combination with a stable emulsion (SE) or a synthetic Toll-like receptor 4 (TLR4) agonist (glucopyranosyl lipid A [GLA]) in SE (GLA-SE).

Medical Condition: 
Medical Treatment: 

Pages

Subscribe to RSS - Plasmodium vivax